Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).  The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.

DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Abbott Labs

Our constant need for medical products will be a major growth driver for these healthcare giants.

2 Top Stocks to Buy and Hold for 10 Years

Going by historical performance, there is a 62% chance of a rise in BMY stock over the next month. Out of 116 instances in the last ten years that BMY stock saw a five-day decline of 5.2% or more, 72 of them resulted in BMY stock rising over the subsequent one month period.

What Bristol Myers Squibb's Q1 Results Say About Its Stock

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at upcoming ACC.21

Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session

Investors will have to wait for the full data set to see how much the drug could really help cancer patients.

This Data Could Accelerate Bristol Myers Squibb's Cancer Drug Opportunity

The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received a price target decrease from $70 to $62. These are the details.

BMY Stock: $62 Target (Down From $70) By Morgan Stanley

bluebird bio

What Investors Need to Know About This $419,500 CAR-T Cancer Treatment

ARK Innovation ETF

Enterprise Products Partners

Lockheed Martin

Altria

Omega Healthcare Investors

Philip Morris

Invesco QQQ

SPDR S&P 500 ETF Trust

Exxon Mobil

Markets have been running to new all-time highs, but there are some risk factors that investors should keep in mind. Moving to cash isn't a great choice, due to rising inflationary pressures.

5 Undervalued Income Stocks That Offer Stability In Uncertain Times

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review BMS's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

There are always deals on Wall Street. Bristol-Myers Squibb seems like one. Rarely do I find such a compelling case for both a company and a stock.

Bristol-Myers: A Compelling Investment Thesis In A Nutshell

The stock price of Bristol-Myers Squibb Co (NYSE: BMY) fell from $66.03 to $62.89 today. This is why it happened.

BMY Stock: From $66.03 To $62.89 Explanation

Bristol-Myers Squibb's (BMY) CEO Giovanni Caforio on Q1 2021 Results - Earnings Call Transcript

The big drugmaker reported disappointing first-quarter results.

Why Bristol Myers Squibb Stock Fell Today

Bristol-Myers Squibb Co (NYSE: BMY) joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the year. Today, Merck & Co Inc (NYSE: MRK) reported Q1 earnings and sales that trailed Wall Street expectations, citing an early-in-the-year pandemic surge.

Bristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs Sales

Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.

Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline

Part of the problem was the company's strong performance a year ago.

What Went Wrong for Bristol Myers Squibb in Q1

The drugmaker Bristol Myers Squibb reported earnings early Thursday that fell short of Wall Street expectations.

Bristol Myers Squibb Stock Fell After Earnings. Here's Why.

Bristol Myers (BMY) delivered earnings and revenue surprises of -3.33% and -0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Miss Estimates

Bristol Myers Squibb on Thursday reported adjusted earnings of $1.74 per share on $11.07 billion in sales for its first quarter. In response, BMY stock fell.

Bristol Myers Stock Dives As First Quarter Comes Up Unexpectedly Light

Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 1.16% year over year to $1.74, which missed the estimate of $1.82.

Bristol-Myers Squibb: Q1 Earnings Insights

Shares of Bristol Myers Squibb Co. shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that came up short of expectations, as the COVID-19 pandemic reduced revenue growth by 5 percentage points. The company swung to net income of $2.02 billion, or 89 cents a share, from a loss of $775 million, or 34 cents a share, in the year-ago period.

Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations

Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

Bristol Myers first-quarter earnings miss expectations as cancer drugs underperform

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports First Quarter Financial Results for 2021

Bristol Myers Squibb Reports First Quarter Financial Results for 2021

AbbVie

Amgen

Johnson & Johnson

Moderna

Pfizer

SoFi Select 500 ETF

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

News for Bristol-Myers Stock (BMY)